Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

by Hussain, Maha , Madziarska, Katarzyna , Fizazi, Karim , Penson, David F , Saad, Fred , Cubero, Daniel I. G , Noerby, Bettina , Zohren, Fabian , Efstathiou, Eleni , Kolinsky, Michael P , Modelska, Katharina , Sugg, Jennifer , Shore, Neal D , Sternberg, Cora N , Ferreira, Ubirajara , Lin, Xun , Steinberg, Joyce , De Giorgi, Ugo

in Adenocarcinoma - drug therapy / Adenocarcinoma - mortality / Aged / Androgen Antagonists - therapeutic use / Androgens / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cancer therapies / Castration / Chemotherapy / Cytotoxicity / Double-Blind Method / FDA approval / Humans / Kallikreins - blood / Kaplan-Meier Estimate / Male / Metastases / Metastasis / Middle Aged / Phenylthiohydantoin - adverse effects / Phenylthiohydantoin - analogs & derivatives / Phenylthiohydantoin - therapeutic use / Placebos / Prostate cancer / Prostate-specific antigen / Prostate-Specific Antigen - blood / Prostatic Neoplasms, Castration-Resistant - drug therapy / Prostatic Neoplasms, Castration-Resistant - mortality / Quality of life / Regulatory approval / Survival / Survival Analysis

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020

Confirm

Do you wish to request the book?

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain, Maha,

Madziarska, Katarzyna,

Fizazi, Karim,

Penson, David F,

Saad, Fred,

Cubero, Daniel I. G,

Noerby, Bettina,

Zohren, Fabian,

Efstathiou, Eleni,

Kolinsky, Michael P,

Modelska, Katharina,

Sugg, Jennifer,

Shore, Neal D,

Sternberg, Cora N,

Ferreira, Ubirajara,

Lin, Xun,

Steinberg, Joyce,

De Giorgi, Ugo

2020

Overview

Among men with high-risk, nonmetastatic, castration-resistant prostate cancer, the addition of enzalutamide to androgen-deprivation therapy improved overall survival by nearly a year as compared with ADT alone: median survival was 67 months with enzalutamide plus ADT and 56 months with ADT alone.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenocarcinoma - drug therapy

/ Adenocarcinoma - mortality

/ Aged

/ Androgen Antagonists - therapeutic use

/ Androgens

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use